LncRNA TATDN1 Contributes to the Cisplatin Resistance of Non-small Cell Lung Cancer Through TATDN1/miR-451/TRIM66 Axis

Overview

Journal Cancer Biol Ther

Specialties Oncology
Pharmacology

Date 2018 Nov 28

PMID 30481109

Citations 26

Authors

Linmei Wang

Xueqin Shang

Qingqing Feng

Affiliations

Soon will be listed here.

Abstract

Background: Chemoresistance has been considered to be a major obstacle for cancer therapy clinically. Long non-coding RNAs (LncRNAs) are asscociated with the development, prognosis and drug-resistance of non-small cell lung cancer (NSCLC). Whereas, the regulatory mechanism of lncRNA TATDN1 in the cisplatin resistance of NSCLC is still not clear.

Methods: The expression of TATDN1, miR-451 and TRIM66 in NSCLC tissues and cell lines were detected by qRT-PCR or western blot. Immunohistochemistry (IHC) assay was performed for the detection of TATDN1 expression profile. 88 patients who underwent cisplatin treatment were followed up to 60-months for the analysis of survival rate. MTT and Flow cytometry analysis were performed for the assessment of cell survival rate, proliferation and apoptosis. Bioinformatics, Dual-Luciferase reporter were employed to analyze the interaction among TATDN1, miR-451 and TRIM66. Xenograft tumor model was constructed to verify the role of TATDN1 in NSCLC treated with cisplatin (DDP) in vivo.

Results: TATDN1 and TRIM66 was significantly upregulated while miR-451 was downregulated in NSCLC tissues and cell lines, especially in DDP-resistant tumor tissues and cells. Survival rates of NSCLC patients with low TATDN1 expression were improved following DDP chemotherapy. TATDN1 upregulated TRIM66 expression via sponge for miR-451. Moreover, TATDN1 knockdown improved DDP-sensitivity in NSCLC patients by regulation of miR-451/TRIM66 axis. Finally, knockdown of TATDN1 improved the sensitivity of NSCLC to DDP in vivo.

Conclusions: TATDN1 enhanced the DDP-tolerance of NSCLC cells by upregulating TRIM66 expression via sponging miR-451, hinting a novel regulatory pathway of chemoresistance in DDP-tolerant NSCLC cells and providing a potential therapeutic target for NSCLC patients with DDP-reistance.

Citing Articles

Comprehensive review of LncRNA-mediated therapeutic resistance in non-small cell lung cancer.

Ge X, Shen Z, Yin Y Cancer Cell Int. 2024; 24(1):369.

PMID: 39522033 PMC: 11549762. DOI: 10.1186/s12935-024-03549-1.

CircSFMBT2 Plays an Oncogenic Role in Lung Adenocarcinoma Depending on the miR-1305/SALL4 Axis.

Zhao X, Xing X, Wu Y Biochem Genet. 2023; 62(5):3485-3503.

PMID: 38127171 DOI: 10.1007/s10528-023-10611-6.

Various LncRNA Mechanisms in Gene Regulation Involving miRNAs or RNA-Binding Proteins in Non-Small-Cell Lung Cancer: Main Signaling Pathways and Networks.

Braga E, Fridman M, Burdennyy A, Loginov V, Dmitriev A, Pronina I Int J Mol Sci. 2023; 24(17).

PMID: 37686426 PMC: 10487663. DOI: 10.3390/ijms241713617.

Hsa_circ_0028007 regulates the progression of nasopharyngeal carcinoma through the miR-1179/SQLE axis.

Li W, Jiang X, Zhao L Open Med (Wars). 2023; 18(1):20230632.

PMID: 37554147 PMC: 10404895. DOI: 10.1515/med-2023-0632.

Human and bacterial TatD enzymes exhibit apurinic/apyrimidinic (AP) endonuclease activity.

Dorival J, Eichman B Nucleic Acids Res. 2023; 51(6):2838-2849.

PMID: 36881763 PMC: 10085689. DOI: 10.1093/nar/gkad133.

References

Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R . Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012; 10:55. PMC: 3340316. DOI: 10.1186/1479-5876-10-55. View

Travis W . Pathology of lung cancer. Clin Chest Med. 2011; 32(4):669-92. DOI: 10.1016/j.ccm.2011.08.005. View

Wu Q, Guo L, Jiang F, Li L, Li Z, Chen F . Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines. J Cell Mol Med. 2015; 19(12):2874-87. PMC: 4687702. DOI: 10.1111/jcmm.12681. View

Wilczynska A, Bushell M . The complexity of miRNA-mediated repression. Cell Death Differ. 2014; 22(1):22-33. PMC: 4262769. DOI: 10.1038/cdd.2014.112. View

Riquelme I, Tapia O, Leal P, Sandoval A, Varga M, Letelier P . miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway. Cell Oncol (Dordr). 2015; 39(1):23-33. PMC: 4751587. DOI: 10.1007/s13402-015-0247-3. View

Pan X, Wang R, Wang Z . The potential role of miR-451 in cancer diagnosis, prognosis, and therapy. Mol Cancer Ther. 2013; 12(7):1153-62. DOI: 10.1158/1535-7163.MCT-12-0802. View

Sun W, Zu Y, Fu X, Deng Y . Knockdown of lncRNA-XIST enhances the chemosensitivity of NSCLC cells via suppression of autophagy. Oncol Rep. 2017; 38(6):3347-3354. PMC: 5783579. DOI: 10.3892/or.2017.6056. View

Li X, Sanda T, Look A, Novina C, von Boehmer H . Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL. J Exp Med. 2011; 208(4):663-75. PMC: 3135352. DOI: 10.1084/jem.20102384. View

Liu M, Li X, Gao T, Cui Y, Ma N, Zhou Y . Elevated HOTAIR expression associated with cisplatin resistance in non-small cell lung cancer patients. J Thorac Dis. 2017; 8(11):3314-3322. PMC: 5179381. DOI: 10.21037/jtd.2016.11.75. View

10.

Bassett A, Akhtar A, Barlow D, Bird A, Brockdorff N, Duboule D . Considerations when investigating lncRNA function in vivo. Elife. 2014; 3:e03058. PMC: 4132285. DOI: 10.7554/eLife.03058. View

11.

Matsuda A, Yamaoka K, Tango T . Quality of life in advanced non-small cell lung cancer patients receiving palliative chemotherapy: A meta-analysis of randomized controlled trials. Exp Ther Med. 2012; 3(1):134-140. PMC: 3438671. DOI: 10.3892/etm.2011.368. View

12.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

13.

Tay Y, Rinn J, Pandolfi P . The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014; 505(7483):344-52. PMC: 4113481. DOI: 10.1038/nature12986. View

14.

Xue W, Li L, Tian X, Fan Z, Yue Y, Zhang C . Integrated analysis profiles of long non-coding RNAs reveal potential biomarkers of drug resistance in lung cancer. Oncotarget. 2017; 8(38):62868-62879. PMC: 5609887. DOI: 10.18632/oncotarget.16444. View

15.

Tian F, Han Y, Yan X, Zhong D, Yang G, Lei J . Upregulation of microrna-451 increases the sensitivity of A549 cells to radiotherapy through enhancement of apoptosis. Thorac Cancer. 2016; 7(2):226-31. PMC: 4773304. DOI: 10.1111/1759-7714.12318. View

16.

Zequn N, Xuemei Z, Wei L, Zongjuan M, Yujie Z, Yanli H . The role and potential mechanisms of LncRNA-TATDN1 on metastasis and invasion of non-small cell lung cancer. Oncotarget. 2016; 7(14):18219-28. PMC: 4951283. DOI: 10.18632/oncotarget.7788. View

17.

Chen Q, Wei C, Wang Z, Sun M . Long non-coding RNAs in anti-cancer drug resistance. Oncotarget. 2016; 8(1):1925-1936. PMC: 5352108. DOI: 10.18632/oncotarget.12461. View

18.

Tan J, Sirey T, Honti F, Graham B, Piovesan A, Merkenschlager M . Extensive microRNA-mediated crosstalk between lncRNAs and mRNAs in mouse embryonic stem cells. Genome Res. 2015; 25(5):655-66. PMC: 4417114. DOI: 10.1101/gr.181974.114. View

19.

Wang W, Zhang L, Wang Y, Ding Y, Chen T, Wang Y . Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer. Cell Death Dis. 2017; 8(10):e3071. PMC: 5680582. DOI: 10.1038/cddis.2017.460. View

20.

Wang Y, Hou J, He D, Sun M, Zhang P, Yu Y . The Emerging Function and Mechanism of ceRNAs in Cancer. Trends Genet. 2016; 32(4):211-224. PMC: 4805481. DOI: 10.1016/j.tig.2016.02.001. View